EUCTR2018-001684-22-BE进行中（未招募）1 期
A Phase 2, partial blind, randomized, placebo-controlled, multicenter study to evaluate the safety and immunogenicity of two novel live attenuated serotype 2 oral poliovirus vaccines candidates, in healthy adults previously vaccinated with oral polio vaccine (OPV) or inactivated polio vaccine (IPV), compared with historical controls given Sabin OPV2 or placebo.
niversity of Antwerp0 个研究点目标入组 332 人开始时间: 2018年5月14日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 332
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.For Groups 1, 2, 3 and 4: healthy males or females, from 18 to 50 years of age inclusive, having previously received at least 3 doses of OPV more than 12 months before the start of the study;
- •2.For Groups 5, 6 and 7: healthy males or females, from 18 to 50 years of age inclusive, having previously received at least 3 doses of IPV more than 12 months before the start of the study;
- •3.Having residence in Belgium;
- •4.In good physical and mental health as determined on the basis of medical history and general physical examination performed at Day 0;
- •5.Female subjects of childbearing potential must agree to the use of an effective method of birth control throughout the study and up to 3 months after last vaccine dose (see Section 7);
- •6.Willing to adhere to the prohibitions and restrictions specified in this protocol (see Section 7);
- •7.Informed Consent Form (ICF) and Code of Conduct signed voluntarily by the subject before any study-related procedure is performed, indicating that the subject understands the purpose of any procedures required for the study and is willing to participate in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 332
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.A condition that, in the opinion of the Investigator, could compromise the well being of the subject or course of the study, or prevent the subject from meeting or performing any study requirements;
- •2.For Groups 5, 6 and 7: ever having received any OPV in the past;
- •3.Any travel to polio endemic countries or countries with evidence of recent (within last 6 months) wild or vaccine-derived poliovirus circulation during the total duration of the study
- •4.Professional handling of food, catering or food production activities during the total duration of the study;
- •5.Having Crohn’s disease or ulcerative colitis or having had major surgery of the gastrointestinal tract involving significant loss or resection of the bowel;
- •6.A known allergy, hypersensitivity, or intolerance to the study vaccine or the placebo, or to any of their components or to any antibiotics;
- •7.Any confirmed or suspected immunosuppressive or immunodeficiency condition (including human immunodeficiency virus [HIV] infection, hepatitis B or C infections or total serum IgA level below lab lower limit of normal (LNN));
- •8.Will have household or professional contact with known immunosuppressed people or people without full polio vaccination (i.e. complete primary infant immunization series), e.g. babysitting during the total duration of the study;
- •9.Neonatal nurses or others having professional contact with children under 6 months old during the total duration of the study;
- •10.Chronic administration (i.e., longer than 14 days) of immunosuppressant drugs or other immune-modifying drugs within 6 months prior to the first vaccine dose or planned use during the study. For instance, for corticosteroids, this means prednisone, or equivalent, = 0.5 mg/kg/day (inhaled and topical steroids are allowed whereas intra-articular and epidural injection/administration of steroids are not allowed);
- •11.Presence of contraindications to administration of the study vaccine on Day 0: acute severe febrile illness deemed by the Investigator to be a contraindication for vaccination or persistent diarrhea or vomiting;
- •12.Indications of drug abuse or excessive use of alcohol at Day 0 (males: > 21 units per week (m); females > 14 units per week);
- •13.Being pregnant or breastfeeding. Women of childbearing potential will undergo a urine pregnancy test at each vaccination visit. Subjects with a positive pregnancy test will be excluded;
- •14. Participation in another clinical study within 28 days prior to entry in this study or receipt of any investigational product (drug or vaccine) other than the study vaccine within 28 days prior to the first administration of study vaccine, or planned use during the study period;
- •15.Administration of any vaccine other than the study vaccine within 28 days prior to the first dose of study vaccine and during the entire study period;
- •16.Administration of any polio vaccine within 12 months before the start of the study;
- •17.Having had a transfusion of any blood product or application of immunoglobulins within the 4 weeks prior to the first administration of study vaccine or during the study;
- •18.Subject is an employee of the Investigator or study site, with direct involvement in th
研究者
相似试验
进行中（未招募）
1 期
A Phase-II, double-blind, randomized, placebo-controlled proof of concept study on the safety and early efficacy of Alkaline Phosphatase in sepsis patients with Renal Failure. - A phase-II db plb-ctrld RCT on Safety and early efficacy of AP in sepsis patients with renal failureSepsis with Renal FailureMedDRA version: 9.1Level: LLTClassification code 10040050Term: Sepsis NOSMedDRA version: 9.1Level: LLTClassification code 10038435Term: Renal failureEUCTR2007-003866-16-BEAM-Pharma B.V.68
进行中（未招募）
1 期
A randomized double-blind placebo controlled study combining EYP001a with polymerase inhibitors to improve hepatitis B cure ratesChronic Hepatitis BMedDRA version: 20.1 Level: PT Classification code 10008910 Term: Chronic hepatitis B System Organ Class: 10021881 - Infections and infestationsEUCTR2019-001629-28-PLENYO Pharma SA49
进行中（未招募）
1 期
GB001 in Adult Subjects with Chronic RhinosinusitisChronic Rhinosinusitis with or without Nasal PolypsMedDRA version: 21.1Level: PTClassification code 10071399Term: Chronic eosinophilic rhinosinusitisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2019-001682-33-CZGB001, Inc.100
尚未招募
2 期
A Phase 2a, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of BG00012 when given with methotrexate to subjects with active rheumatoid arthritis who have had an inadequate response to conventional disease-modifying anti-rheumatic drug therapy.Inflammatory and Immune System - Rheumatoid arthritisRheumatoid arthritisACTRN12608000644369Biogen Idec, Inc150
进行中（未招募）
1 期
Study of RVT-101 in patients with dementia with Lewy Bodies ( DLB).Dementia with Lewy BodiesMedDRA version: 19.0Level: PTClassification code 10067889Term: Dementia with Lewy bodiesSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-005495-19-NLAxovant Sciences, Inc.240